Tagrisso is only available as a brand-name drug. It doesn’t come in a generic version. A generic drug is an exact copy of the active ingredient in a brand-name medication. Generics tend to cost ...

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targeted ...

AstraZeneca's EGFR inhibitor Tagrisso has become the go-to therapy for EGFR-mutated non-small cell lung cancer (NSCLC), but now has competition from Johnson & Johnson's Rybrevant and Lazcluze ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Tagrisso (osimertinib) for expanded use in lung cancer. The regulatory body has approved Tagrisso for the treatment of ...

Cyramza plus Tagrisso significantly extended PFS in TKI-naïve EGFR-mutant NSCLC patients compared to Tagrisso alone, with a median PFS of 24.8 vs. 15.6 months. PFS benefits were consistent across ...

In 2023, TAGRISSO® plus ORPATHYS® received Fast Track designation from the US Food and Drug Administration (FDA) in this setting. ORPATHYS® is an oral, potent, and highly selective MET tyrosine ...

Drug Sales Estimates: Tagrisso, Lynparza & Other Key Drugs Sales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi — and diabetes medicine Farxiga ...